📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Vir Biotechnology announces CMO departure, seeks replacement

EditorLina Guerrero
Published 02/20/2024, 04:41 PM
© Reuters.

SAN FRANCISCO - Vir Biotechnology, Inc. (NASDAQ: NASDAQ:VIR), a company specializing in immunology and infectious diseases, announced the upcoming departure of its Chief Medical Officer, Phil Pang, M.D., Ph.D., who will be leaving the company at the end of March 2024 to focus on family time. The firm is actively searching for his successor.

Dr. Pang has been recognized for his leadership role in the development of sotrovimab, a therapeutic agent used during the height of the COVID-19 pandemic. His expertise in infectious diseases contributed to the company's efforts to address global health challenges such as chronic hepatitis delta, hepatitis B, and HIV. "He leaves behind a strong team of drug developers, positioning us well for continued success," remarked Marianne De Backer, Vir's CEO.

Reflecting on his tenure, Dr. Pang expressed pride in the company's achievements and confidence in the team's ability to maintain momentum in the transition period. "I am inspired by Marianne's vision of the future at Vir, and I look forward to continuing to watch the company flourish," he said.

Vir Biotechnology focuses on leveraging the immune system to treat and prevent serious infectious diseases. The company has established two technology platforms aimed at enhancing immune responses, and its clinical pipeline includes candidates targeting hepatitis delta and B viruses, as well as HIV. Vir also has several preclinical candidates, including those for influenza, COVID-19, RSV/MPV, and HPV.

It should be noted that early-stage clinical trial results may not be indicative of full results from later-stage trials and do not guarantee regulatory approval. Vir has not disclosed any further details regarding the transition or potential candidates for the CMO position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.